We're at an inflection point in terms of our ability to use new approaches that are enabled by high throughput screening, by computational toxicology, and by a better understanding of mode of action and how chemicals can trigger the same sequence of events within a body to result in a particular toxic effect. All of that is the subject right now, I think, of several billion dollars worth of work in the U.S. It is moving very fast. I think it is something that the Canadian government has been watching quite closely. It is engaged both bilaterally on it and through the OECD and can monitor that work and understand how it might be applied in a regulatory context.
The science has to be ready for it to be applied in a regulatory context. You have to have the confidence in the new approaches, that they can replicate at least what the old approaches did, and then go beyond those. I think all of that is happening. So the question for us, I think, is how to be part of that and to make sure that we can pick up the best developments as they happen. The OECD is probably an excellent place to do that, but possibly there's some bilateral work that could be done as well.